By Professor Elgene Lim

Conference Abstracts

Lim E; Beeram M; Prawira A; Patnaik A; Wang XA; Young SRL; Smyth LM; Hamilton EP, 2021, 'EMBER: A phase 1a/b trial of LY3484356, a novel, oral selective estrogen-receptor degrader (SERD), in advanced ER plus breast cancer and endometroid endometrial cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700055&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Portman N; Milioli H; Alexandrou S; Coulson R; Yong A; Fernandez K; Chia K; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley W; Swarbrick A; Caldon L; Lim E, 2021, 'Mdm2 inhibition synergises with endocrine therapy or cdk4/6 inhibition for the treatment of estrogen receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700638&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lau B; Segara D; Ong A; Bingham J; Kiely B; Carson E-K; Chen J; Mak C; Warrier S; Hui M; Middleton K; Parker A; Mann B; Lindeman G; Tilley W; Lim E, 2021, 'Winpro: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 81, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Palmieri C; Linden H; Birrell S; Lim E; Schwartzberg LS; Rugo HS; Cobb P; Jain K; Vogel C; O'Shaughnessy JA; Getzenberg RH; Steiner MS; Brufsky A; Overmoyer B, 2020, 'Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 81, presented at San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 08 December 2020 - 11 December 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000618737700249&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E, 2020, 'A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology, Chicago, presented at American Society of Clinical Oncology, Chicago, 29 May 2020 - 31 May 2020

Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), Vol. 4, pp. or05 - or06, presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982

Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'Abstract GS2-03: The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 80, pp. gs2-03-gs2-03, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.sabcs19-gs2-03

Lok SW; Baron-Hay S; Lim E; Blum R; Boyle F; Clarke K; Cuff K; Green M; Malik L; Mok K; Murray N; Nott L; Nottage M; Tafreshi A; Tsoi D; Yeo B; Gibbs P; De Boer R, 2019, 'A 'real world' experience of CDK4/6 inhibition with ribociclib and endocrine therapy in hormone receptor positive metastatic breast cancer in Australia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-OT2-02-01

Jhaveri K; Winer EP; Lim E; Fidalgo JA; Bellet M; Mayer IA; Boni V; Patel JM; Bardia A; Garcia JM; Kabos P; Gates M; Chen Y-C; Fredrickson J; Wang X; Friedman LS; Spoerke J; Gendreau S; Metcalfe C; Liu L; Chang C-W; Monemi S; Gonzalez M; McCurry U; Milan S; Humke EW; Loi S, 2019, 'A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-PD7-05

Wahlroos S; Wilkinson A; Milioli H; Portman N; Gallego-Ortega D; Lim E, 2019, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P4-14-13

Lim E; Boyle F; Okera M; Loi S; Goksu SS; van Hal G; Hartman DG; Gable JC; Price GL; Hossain A; Gainford MC; Ezquerra MB, 2019, 'The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-P5-14-05

Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043

Milioli HH; Chia KM; Portman N; Young A; Laven-Law G; Selth L; Tilley WD; Hickey T; Lim E, 2019, 'Androgen receptor activation in Endocrine-Resistant ER-positive breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P034

Stirzaker C; Chia KM; Portman N; Milioli HH; Clifton S; Achinger-Kawecka J; Nair S; Lim E; Clark S, 2019, 'DNA demethylation agents as a therapeutic approach in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P049

Alexandrou S; Milioli HH; Portman N; Lee C; Fernandez K; Blake D; Lim E; Caldon L, 2019, 'S phase dysregulation occurs following resistance to CDK4/6 inhibition ER+ breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P001

Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, Bioscientifica, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012

Chia KM; Milioli H; Portman N; Laven-Law G; Yong A; Swarbrick A; Caldon L; Tilley W; Hickey T; Lim E, 2018, 'Abstract P6-20-04: Activation of AR inhibits growth of endocrine-resistant breast cancer', in Cancer Research, American Association for Cancer Research (AACR), TX, San Antonio, Vol. 79, pp. p6-20-04-p6-20-04, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-20-04

Wahlroos S; Wilkinson A; Gallego-Ortega D; Febbraio M; Lim E, 2018, 'Concurrent exercise and chemotherapy in preclinical breast cancer models', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P6-21-05

Swarbrick A; Wu SZ; Roden D; Al-Eryani G; O'Toole S; Lim E, 2018, 'Landscape of the breast tumour microenvironment at single-cell resolution', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-GS1-01

Metzger O; Mandrekar S; Loibl S; Mundhenke C; Seiler S; Valagussa P; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller K; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Delalogue S; Vaz-Luis I; Dockter T; Lanzillotti J; Ciruelos E; DeMichele AM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib+antiHER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-OT3-02-07

Swarbrick A; Cazet A; Hui M; O'Toole S; Lim E; Martin M, 2018, 'Small molecule inhibition of smoothened in triple negative breast cancer-associated fibroblasts depletes cancer stem cells and sensitizes to cytotoxic chemotherapy in mice and humans', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-P5-07-03

Carson E; Segara D; Parker A; O'Toole S; Coates A; Mann B; Lindeman G; Tilley W; Lim E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-OT1-01-03

Lim E; Carson E, 2018, 'The WinPro study: A window of opportunity study of endocrine therapy with and without prometrium in postmenopausal women with early stage hormone receptor-positive breast cancer', in Asia-Pacific Journal of Clinical Oncology, Wiley, Perth Convention and Exhibition Centre, Perth, Western Australia, Vol. 14, pp. 194 - 195, presented at COSA's 45th Annual Scientific Meeting, Perth Convention and Exhibition Centre, Perth, Western Australia, 13 November 2018 - 15 November 2018, http://dx.doi.org/10.1111/ajco.13089

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2+therapy plus endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR1)/HER2-positive metastatic breast cancer (MBC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, GERMANY, Munich, Vol. 29, pp. 121 - 121, presented at 43rd ESMO Congress (ESMO), GERMANY, Munich, 19 October 2018 - 23 October 2018, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459277300360&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Loibl S; Metzger O; Mandrekar SJ; Mundhenke C; Seiler S; Valagussa P; DeMichele A; Lim E; Tripathy D; Winer EP; Huang C; Carey L; Francis P; Miller KD; Goetz MP; Prat A; Loi S; Krop I; Gianni L; Ciruelos EM, 2018, 'PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)', in Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii121, http://dx.doi.org/10.1093/annonc/mdy272.357

Lim E; Portman N; Alexandrou S; Haupt S; Haupt Y; Caldon E, 2017, 'Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 78, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 05 December 2017 - 09 December 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000425489401175&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Anderson RL; Swarbrick A; Johnstone R; Chua B; Gill A; Saunders C; Lakhani S; Lim E; Loi S; O'Toole SA; Khanna KK; Devereux L; Harvey K; Reed AM, 2017, 'Brocade: The National Breast Cancer Foundation Repository of Primary Tumours and Metastases from Breast Cancer Patients', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 110 - 111, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500136&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lin FP-Y; Martin C; Kocbek S; Joshua AM; Dear RF-G; Lim E; Chantrill LA; Chin VT; Epstein RJ, 2017, 'Identifying determinants of quality of life in patients undergoing systemic therapy for solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 35, presented at 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, IL, Chicago, 02 June 2017 - 07 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.6596

Seah D; Robinson D; Churilov L; Lin NU; Lim E, 2016, 'ATTITUDES OF PATIENTS WITH METASTATIC CANCER TOWARD RESEARCH BIOPSIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 12, pp. 107 - 108, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900139&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lim E, 2016, 'TRANSLATING MOLECULAR INSIGHTS IN ESTROGEN RECEPTOR SIGNALING INTO CLINICAL TRIALS IN BREAST CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 12, pp. 82 - 83, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387769900058&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cao SA; Lim E; Brown M; Bailey ST, 2014, 'Modeling chemoendocrine therapy for ER+/p53wt luminal breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 75, presented at 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2014 - 13 December 2014, http://dx.doi.org/10.1158/1538-7445.SABCS14-P3-05-14

Chi D; He H; Yeung T; Jeselsohn R; Schnitt S; Garber J; Richardson A; Lim E; Brown M, 2013, 'Abstract 2313: Differences in estrogen receptor signaling in normal mammary epithelial cells and ER-positive primary breast tumors and metastases.', in Cancer Research, American Association for Cancer Research (AACR), Vol. 73, pp. 2313 - 2313, http://dx.doi.org/10.1158/1538-7445.am2013-2313

Johnson SF; Johnson N; Chi D; Primack B; D'Andrea AD; Lim E; Shapiro GI, 2013, 'The CDK inhibitor dinaciclib sensitizes triple-negative breast cancer cells to PARP inhibition', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, Vol. 73, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-1788

Preprints

Wang T; Harvey K; Reeves J; Roden DL; Bartonicek N; Yang J; Al-Eryani G; Kaczorowski D; Chan C-L; Powell J; O’Toole S; Lim E; Swarbrick A, 2023, An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research, http://dx.doi.org/10.1101/2023.04.06.535805

Hurwitz J; Haggstrom LR; Lim E, 2023, Antibody Drug Conjugates: Ushering in a New Era of Cancer Therapy, http://dx.doi.org/10.20944/preprints202306.0232.v1

Lim E; Boyle F; Okera M; Loi S; Goksu SS; Hal GV; Chapman S; Gable J; Chen Y; Price G; Hossein A; Gainford C; Ezquerra MB, 2022, An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with Advanced Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-1440521/v1

Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., http://dx.doi.org/10.21203/rs.3.rs-1789675/v1

San Juan B; Hediyeh-Zadeh S; Rangel L; Milioli H; Rodriguez V; Bunkum A; Kohane F; Purcell C; Bhuva D; Kurumlian A; Castillo L; Lim E; Gill A; Ganju V; Dear R; O’Toole S; Vargas C; Hickey T; Goldstein L; Lock J; Davis M; Chaffer C, 2022, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease, http://dx.doi.org/10.1101/2022.03.21.22269988

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Abuelmaaty S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2020, VGLL1 drives therapy resistance in estrogen receptor positive breast cancer, http://dx.doi.org/10.1101/2020.11.29.402842

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v2

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized inBRCA1mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Cazet A; Hui M; Elsworth B; Wu S; Roden D; Chan C-L; Skhinas J; Collot R; Yang J; Harvey K; Johan Z; Cooper C; Nair R; Herrmann D; McFarland A; Deng N-T; Ruiz-Borrego M; Rojo F; Trigo J; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins N; Cox T; Samuel M; Martín M; Swarbrick A, 2017, Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer, http://dx.doi.org/10.1101/215954

Other

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.c.7585327

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032298

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032295

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032292

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032289

Gemma C; Lai C-F; Singh AK; Belfiore A; Portman N; Milioli HZ; Periyasamy M; Raafat S; Nicholls AJ; Davies CM; Patel NR; Simmons GM; Fan H; Nguyen VTM; Magnani L; Rakha E; Martin L-A; Lim E; Coombes RC; Pruneri G; Buluwela L; Ali S, 2024, Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer, http://dx.doi.org/10.1158/0008-5472.28032286

Back to profile page